tumor mutational burden
TMB-High Status Does Not Predict Opdivo-Yervoy Response in Pan-Tumor Analysis
In a retrospective analysis, tumor mutational burden was not associated with improved responses to combination immunotherapy, researchers found.
In a study presented at AACR, immunotherapy responses across 20 cancer types were consistently higher for tumors with TMB of at least 16 somatic mutations per megabase.Â
A recent study suggests the lack of diversity in public databases may affect the accuracy of TMB scores and lead to inappropriate treatment for racial minorities.
Researchers are increasingly arguing that the tissue-agnostic approval was too broad, and that tumor mutational burden is only a biomarker of response to immunotherapy in a handful of cancer types.
A TMB-high cutoff of 10 mutations per megabase doesn't predict immunotherapy responses universally well across cancer types, according to a paper published in JAMA Oncology.